These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon. van Leeuwen Y; Rosendaal FR; van der Meer FJ Thromb Res; 2008; 123(2):225-30. PubMed ID: 18407321 [TBL] [Abstract][Full Text] [Related]
4. Warfarin or acenocoumarol: which is better in the management of oral anticoagulants? Barcellona D; Vannini ML; Fenu L; Balestrieri C; Marongiu F Thromb Haemost; 1998 Dec; 80(6):899-902. PubMed ID: 9869157 [TBL] [Abstract][Full Text] [Related]
5. [Warfarin or acenocoumarol is better in the anticoagulant treatment of chronic atrial fibrillation?]. Lengyel M; Orv Hetil; 2004 Dec; 145(52):2619-21. PubMed ID: 15724697 [TBL] [Abstract][Full Text] [Related]
6. Transition from acenocoumarol to warfarin in a 12-year-old child. Hakacova N; Björkhem G; Hanséus K Congenit Heart Dis; 2011; 6(6):661-4. PubMed ID: 21501391 [TBL] [Abstract][Full Text] [Related]
7. [The efficacy and safety of acenocoumarol and warfarin therapy in patients with lower limb deep vein thrombosis]. Bernát SI; Rókusz L Orv Hetil; 2012 May; 153(20):786-90. PubMed ID: 22580505 [TBL] [Abstract][Full Text] [Related]
8. [Effect of the -1639G > A polymorphism of the VKORC1 gene on the dose of oral anticoagulants acenocoumarol, and warfarin in Chilean patients: alternative models of inheritance]. López-Hernández D Rev Med Chil; 2016 Apr; 144(4):539-41. PubMed ID: 27401392 [No Abstract] [Full Text] [Related]
9. [Oral anti-coagulation as a primary care service. A necessity that cannot be postponed]. Melguizo Jiménez M; Ortega del Moral A; Castro Gómez JA; Aguilar Navas L Aten Primaria; 2007 Aug; 39(8):453. PubMed ID: 17692240 [No Abstract] [Full Text] [Related]
10. Point-of-care testing and INR within-subject variation in patients receiving a constant dose of vitamin K antagonist. van den Besselaar AM; Biedermann JS; Kruip MJ Thromb Haemost; 2015 Nov; 114(6):1260-7. PubMed ID: 26202616 [TBL] [Abstract][Full Text] [Related]
11. [Long-term anticoagulant therapy in old age]. Bán A Orv Hetil; 1984 Jan; 125(4):205-10. PubMed ID: 6694840 [No Abstract] [Full Text] [Related]
12. VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients. Markatos CN; Grouzi E; Politou M; Gialeraki A; Merkouri E; Panagou I; Spiliotopoulou I; Travlou A Pharmacogenomics; 2008 Nov; 9(11):1631-8. PubMed ID: 19018719 [TBL] [Abstract][Full Text] [Related]
18. The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Montes R; Ruiz de Gaona E; Martínez-González MA; Alberca I; Hermida J Br J Haematol; 2006 Apr; 133(2):183-7. PubMed ID: 16611310 [TBL] [Abstract][Full Text] [Related]
19. The value of pharmacogenetic testing. Pocinki AG JAMA Intern Med; 2015 Feb; 175(2):314. PubMed ID: 25642672 [No Abstract] [Full Text] [Related]
20. The value of pharmacogenetic testing—reply. Kazi DS; Hlatky MA JAMA Intern Med; 2015 Feb; 175(2):314-5. PubMed ID: 25642673 [No Abstract] [Full Text] [Related] [Next] [New Search]